159 related articles for article (PubMed ID: 30864703)
1. Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Urdiciain A; Erausquin E; Meléndez B; Rey JA; Idoate MA; Castresana JS
Int J Oncol; 2019 May; 54(5):1797-1808. PubMed ID: 30864703
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
[TBL] [Abstract][Full Text] [Related]
3. A novel HDAC6 inhibitor Tubastatin A: Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses Temozolomide-induced ER stress-tolerance in GBM cells.
Li ZY; Zhang C; Zhang Y; Chen L; Chen BD; Li QZ; Zhang XJ; Li WP
Cancer Lett; 2017 Apr; 391():89-99. PubMed ID: 28131906
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN.
Zhang G; Gan YH
Oncol Rep; 2017 Nov; 38(5):2657-2666. PubMed ID: 29048666
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Wang Z; Hu P; Tang F; Lian H; Chen X; Zhang Y; He X; Liu W; Xie C
Cancer Lett; 2016 Aug; 379(1):134-42. PubMed ID: 27267806
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
[TBL] [Abstract][Full Text] [Related]
7. HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway.
Yang W; Liu Y; Gao R; Yu H; Sun T
Cancer Lett; 2018 Feb; 415():164-176. PubMed ID: 29222038
[TBL] [Abstract][Full Text] [Related]
8. HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
Leyk J; Daly C; Janssen-Bienhold U; Kennedy BN; Richter-Landsberg C
Cell Death Dis; 2017 Aug; 8(8):e3028. PubMed ID: 29048427
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress.
Sharma R; Chiang YH; Chen HC; Lin HY; Yang WB; Nepali K; Lai MJ; Chen KY; Liou JP; Hsu TI
Cancer Lett; 2024 Apr; 586():216666. PubMed ID: 38311053
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma.
Auzmendi-Iriarte J; Saenz-Antoñanzas A; Mikelez-Alonso I; Carrasco-Garcia E; Tellaetxe-Abete M; Lawrie CH; Sampron N; Cortajarena AL; Matheu A
Cell Death Dis; 2020 Jun; 11(6):417. PubMed ID: 32488056
[TBL] [Abstract][Full Text] [Related]
12. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Liu JR; Yu CW; Hung PY; Hsin LW; Chern JW
Biochem Pharmacol; 2019 May; 163():458-471. PubMed ID: 30885763
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells.
Yang WB; Wu AC; Hsu TI; Liou JP; Lo WL; Chang KY; Chen PY; Kikkawa U; Yang ST; Kao TJ; Chen RM; Chang WC; Ko CY; Chuang JY
Cell Death Dis; 2021 Sep; 12(10):884. PubMed ID: 34584069
[TBL] [Abstract][Full Text] [Related]
14. HDAC6 inhibition induces the failure of mouse early embryonic development.
Wang H; Ling L; Ai L; Bai L
J Cell Physiol; 2019 Jun; 234(6):8752-8759. PubMed ID: 30370558
[TBL] [Abstract][Full Text] [Related]
15. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Zhang D; Dai D; Zhou M; Li Z; Wang C; Lu Y; Li Y; Wang J
Cell Physiol Biochem; 2018; 51(6):2496-2508. PubMed ID: 30562739
[TBL] [Abstract][Full Text] [Related]
17. HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation.
Alothaim T; Charbonneau M; Tang X
Sci Rep; 2021 May; 11(1):10956. PubMed ID: 34040090
[TBL] [Abstract][Full Text] [Related]
18. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.
Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH
Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone deacetylase reduces lipopolysaccharide-induced-inflammation in primary mammary epithelial cells by regulating ROS-NF-кB signaling pathways.
Wang J; Zhao L; Wei Z; Zhang X; Wang Y; Li F; Fu Y; Liu B
Int Immunopharmacol; 2018 Mar; 56():230-234. PubMed ID: 29414656
[TBL] [Abstract][Full Text] [Related]
20. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Tang J; Shi Y; Liu N; Xu L; Zang X; Li P; Zhang J; Zheng X; Qiu A; Zhuang S
Clin Sci (Lond); 2018 Feb; 132(3):339-359. PubMed ID: 29358506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]